[An excerpt of the European Association for the Study of the Liver's clinical practice guidelines on liver vascular diseases in 2025].

作者：B H Luo, G H Han · 发表于：PubMed · 年份：2026 · DOI：10.3760/cma.j.cn501113-20251226-00550 · 研究领域：Liver Disease and Transplantation、Amoebic Infections and Treatments、Organ Transplantation Techniques and Outcomes

Liver vascular diseases include portal vein thrombosis (with or without cirrhosis), portal-sinusoidal vascular disease, Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, non-obstructive sinusoidal dilatation and peliosis hepatis, visceral artery aneurysms, and hepatic arteriovenous fistulas. Importantly, with the exception of portal vein thrombosis in cirrhosis, the others are rare conditions. A substantial body of evidence has been published on the diagnosis, pharmacological treatment, and interventional therapy of liver vascular disorders since the European Association for the Study of the Liver issued the previous version of the clinical practice guidelines in 2016. These guidelines are based on a comprehensive review of relevant literature, providing recommendations for key clinical challenges and emphasizing implementation of individualized treatment by combining individual risk factors and clinical presentations. Thus, multidisciplinary collaborative management involving hepatologists, hematologists, pathologists, interventional radiologists, and surgeons is crucial in this field. The aim of this guideline is to provide guidance for the management of liver vascular diseases based on the best available evidence.